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Purpose: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb 
failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces 
the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the 
effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb 
 morphology, postoperative medications, and complications was evaluated.
Methods: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C 
were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed 
exclusively by one experienced glaucoma specialist using a standardized technique. Patients 
in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 
received 5-FU and subconjunctival injection of bevacizumab.
Results: Group 1 had 6.4 ± 3.3 (0–15) (mean ± standard deviation and range, respectively) 5-FU 
injections. Group 2 had 4.0 ± 2.8 (0–12) (mean ± standard deviation and range, respectively) 
5-FU injections. The added injection of bevacizumab significantly reduced the mean number 
of 5-FU injections by 2.4 ± 3.08 (P # 0.005). There was no significantly lower IOP in group 2 
when compared to group 1. A significant reduction in vascularization and in cork screw vessels 
could be found in both groups (P , 0.0001, 7 days to last 5-FU), yet there was no difference 
between the two groups at the last follow-up. Postoperative complications were significantly 
higher for both groups when more 5-FU injections were applied. (P = 0.008). No significant 
difference in best corrected visual acuity (P = 0.852) and visual field testing (P = 0.610) between 
preoperative to last follow-up could be found between the two groups.
Conclusion: The postoperative injection of bevacizumab reduced the number of subconjunctival 
5-FU injections significantly by 2.4 injections. A significant difference in postoperative IOP 
reduction, bleb morphology, and postoperative medication was not detected.
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Introduction
Glaucoma is a heterogeneous group of ocular disorders leading to optic neuropathy and, 
if left untreated, leading to visual field loss. To prevent the progression of glaucoma, 
lowering the intraocular pressure (IOP) is inevitable.1 In many cases, IOP lowering 
 cannot be achieved without glaucoma filtering surgery. In 1968, Cairns introduced 
the trabeculectomy (TET), which is still the gold standard in glaucoma surgery.2 
 Nevertheless, conjunctival scarring remains the most frequent cause for bleb failure 
after TET. The transdifferentiation of fibroblasts into myofibroblasts is mainly respon-
sible for scar formation leading to bleb failure and a rise in IOP.3 Intra- and postopera-
tively applied antimetabolites, such as 5-fluorouracil (5-FU) and mitomycin C (MMC) 
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have been shown to reduce postoperative scar  formation.4 
Due to their nonspecific effect on cell biology, the application 
can lead to cell damage followed by bleb leakage, hypotony, 
corneal scarring, and endophthalmitis.5,6 Thus, their applica-
tion is limited and alternatives are needed.
Vascular endothelial growth factor (VEGF) is a cytokine 
with multiple effects on wound healing.7,8 Through collagen 
deposition, angiogenesis, and epithelialization scar forma-
tion is stimulated.7 VEGF has been shown to be elevated 
in glaucoma patients and to enhance scar formation.9–11 
Bevacizumab (Avastin; Genentech, San Francisco, CA, 
USA) is a full length humanized monoclonal antibody that 
binds to all isoforms of VEGF. It has been approved by the 
US Food and Drug Administration for intravenous treatment 
of metastatic colorectal cancer.12 Current case reports have 
shown evidence of reduced bleb failure after subconjunctival 
injections of bevacizumab.13–15 Further studies in the rabbit 
and in vitro studies have shown a reduction in postoperative 
scarring and bleb failure using bevacizumab alone or as an 
adjunct to 5-FU.16,17,21–23
The aim of this study was to assess if a single postop-
erative injection of bevacizumab reduces the number of 
postoperative subconjunctival 5-FU injections in glaucoma 
patients. Further, we evaluated the effect of bevacizumab as 
an adjunct to 5-FU on the IOP outcome, bleb morphology, 
postoperative medication, and complications.
Patients and methods
Glaucoma patients (N = 61) who underwent TET with MMC 
were analyzed in a nonrandomized, retrospective, compara-
tive study with a mean follow-up period of 25 ± 19 months. 
Inclusion criteria were patients over 18 years with primary 
open angle glaucoma, pseudoexfoliation glaucoma, normal 
tension glaucoma, pigment dispersion glaucoma, ocular 
hypertension, and primary angle closure glaucoma. Surgery 
was performed exclusively by one experienced glaucoma 
specialist (F. Grehn) using a standardized technique at the 
University Eye Hospital, Wuerzburg, Germany. All  surgeries 
were performed under general anesthesia. Postoperative 
examinations were performed at the clinic of the surgeon who 
performed the TET. Postoperatively, one group of patients 
received subconjunctival applications of 5-FU exclusively 
(group 1). The other group of patients received subconjunc-
tival 5-FU and a single injection of subconjunctival bevaci-
zumab (group 2). Each injection of 0.5 mL 5-FU contained 
5.0 mg 5-FU in 0.9% sodium chloride solution (Cytostatica 
Pharmacy, University Hospital Wuerzburg, Wuerzburg, 
Germany). Each injection of 0.14 mL bevacizumab contained 
3.5 mg of bevacizumab (Avastin; Genentech, San Francisco, 
CA, USA). Patients received detailed explanations and coun-
seling, and informed consent was given for all procedures. 
Patients were divided into the two subgroups according to 
time: before 2008, patients received subconjunctival 5-FU 
and after 2008, patients received adjunctive bevacizumab 
injections as a standard procedure. Best corrected visual 
acuity (BCVA), IOP, number of antiglaucomatous medica-
tions, and visual field examination were analyzed pre- and 
postoperatively, at days 1 and 7 after 1, 3, 6, and 12 months, 
and at the last follow-up. The Wuerzburg bleb classifica-
tion score (WBCS) was used for standardized filtering bleb 
analysis at the same time as the other examinations.18 It is 
a grading system for clinical bleb morphology, and evalu-
ates vascularization, corkscrew vessels, encapsulation, and 
microcysts.18,19 IOP was measured by Goldmann applanation 
tonometry after topical fluorosceine oxybuprocaine (SDU 
Faure, OmniVision AG, Neuhausen, Switzerland). Visual 
field screening was performed with the Octopus® 101 and 900 
perimeter (Haag-Streit UK, Essex, UK). Complete success 
was defined as (1) an IOP # 21 mmHg and .20% pressure 
reduction from baseline without glaucoma medication or 
(2) IOP # 18 mmHg without glaucoma medication. Qualified 
success was defined as (1) an IOP # 21 mmHg and .20% 
pressure reduction from baseline with or without glaucoma 
medication or (2) IOP # 18 mmHg with and without glau-
coma medication.
Multiple comparison t-tests were performed to test 
for significance between treatment pairs. Poisson regres-
sion was performed to model count data for postoperative 
 complications. The Wilcoxon test was used to compare the 
changes in WBCS over time. The level of significance applied 
to the statistical analysis was P # 0.05.
Results
In this study, 61 glaucoma patients who underwent TET 
were analyzed retrospectively. In group 1, 34 glaucoma 
patients received subconjunctival 5-FU only. In group 2, 27 
 glaucoma patients received subconjunctival bevacizumab 
as an adjunct to subconjunctival 5-FU. All patients received 
 topical MMC intraoperatively. Demographics and patient 
data, summarized in Table 1, revealed no statistically signifi-
cant differences between the two groups preoperatively.
Group 1 had 6.4 ± 3.3, 0–15 (mean ± SD, range) 5-FU 
injections and group 2 had 4.0 ± 2.8, 0–12 (mean ± SD, 
range) 5-FU injections. The added injection of bevacizumab 
significantly reduced the mean number of 5-FU injections 
by 2.4 ± 3.08 (P # 0.005). Patients in group 2 received 
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one bevacizumab injection. Topical steroids were applied 
as standard to each patient’s eye in both groups (6–8 times 
a day). Patients with intolerance to preservatives received 
Dexasine® SE (Alcon Pharma GmBH, Freiburg im Breisgau, 
Germany). All other patients received 10 mg/mL Inflanefran® 
forte (Allergan Pharmaceuticals, Irvine, CA, USA).
In group 1, preoperative IOP was lowered from 
24 ± 6.0 mmHg, 15–37 mmHg (mean ± SD, range) to 
12 ± 2.0 mmHg, 8–17 mmHg (mean ± SD, range) at last 
follow-up (Table 2). In group 2, preoperative IOP was 
lowered from 24 ± 6.0 mmHg, 14–37 mmHg (mean ± SD, 
range) to 11 ± 3.0 mmHg, 6–16 mmHg (mean ± SD, range) 
at last follow-up (Table 2). For both groups, preoperative 
IOP was lowered from 24 ± 6.0, 14–37 (mean ± SD, range) 
to 12 ± 3.0, 6–17 (mean ± SD, range) at last follow-up 
(Table 2).  Success rates are summarized in Table 2 and 
Figure 1. Pre- to postoperative changes in IOP are illus-
trated in Table 2. There was no significantly lower IOP in 
group 2 when compared to group 1 at 12 months and at last 
follow-up.
The BCVA in group 1 remained stable at mean decimal 
vision of 0.8 (N = 34) preoperatively to after approximately 
12 months (N = 12), and at last follow-up (N = 24). In 
group 2, BCVA changed from mean decimal vision of 0.62 
(N = 27) preoperatively to 0.56 (N = 17) after 12 months, 
and to 0.35 (N = 17) at last follow-up. No significant dif-
ference in BCVA (P = 0.852) between preoperative to last 
follow-up could be found between the two groups. Data is 
illustrated in Table 2.
The visual field screening in group 1 changed from a 
mean deviance (MD) of 7.5 ± 7.0, -1.1 to 22.1 (mean ± SD, 
range; N = 31) preoperatively to 8.2 ± 6.3, 1.3–21.7 
(mean ± SD, range; N = 22) at last follow-up. Visual field 
screening in group 2 changed from a MD of 10.5 ± 7.6, 
0–23.9 (mean ± SD, range; N = 25) preoperatively to 
12.0 ± 7.7, 0.9–24.0 (mean ± SD, range; N = 15) at last 
 follow-up. No significant difference in visual field screen-
ing (P = 0.610) between preoperative to last follow-up 
could be found between the two groups. Data are illustrated 
in Table 2.
The Wilcoxon test showed a significant reduction in 
vascularization and cork screw vessels in both groups 
(P , 0.001, 7 days to last follow-up). Vascularizations in 
group 1 were significantly higher from day 1 until 3 months 
postoperatively in comparison to last follow-up, and from 
day 1 until 1 month in comparison to last follow-up in 
group 2. Cork screw vessels in group 1 were significantly 
higher from day 7 until 1 month postoperatively in compari-
son to last follow-up, and from day 1 until 1 month in group 
2 in comparison to last follow-up. The lack of significance 
between the postoperative results when compared to the last 
follow-up may be due to the small sample size of evaluated 
blebs postoperatively. There was no difference between the 
two groups at last follow-up. The Wilcoxon test showed 
no significant difference in encapsulation (P = 0.391) and 
microcysts (P = 0.745) between 7 days and last follow-up. 
Results are shown in Figure 2.
Patients in both groups received 0.6 ± 1.0, 1–4 
(mean ± SD, range) surgical interventions after TET. In eyes 
where  re-interventions occurred significantly more often, 
when more injections of 5-FU were applied (P = 0.008) in 
both groups. The types of re-interventions are summarized 
in Table 3. Preoperatively, group 1 received 2.1 ± 1.0, 
0–4 (mean ± SD, range) and group 2 received 2.5 ± 0.9, 
1–4 (mean ± SD, range) antiglaucomatous medications. 
 Postoperatively, group 1 received 0.1 ± 0.4, 0–2 (mean ± SD, 
range) and group 2 received 0.2 ± 0.5, 0–2 (mean ± SD, 
range) antiglaucomatous medications respectively. There was 
no significant difference between the groups pre- (P = 0.121) 
and postoperatively (P = 0.434).
Table 1 Baseline patient characteristics (n = 61)
Age, years (mean ± SD) 67 ± 9.7
 range, years 35–86
Sex, male/female, n 25/36
Follow-up, months (mean ± SD) 25 ± 19.1
 range, months 1–81
Eye, OD/OS, n 26/35
Previous surgeries, n (mean ± SD) 1 ± 1.0
 range 0–4
Previous argon laser trabeculoplasty, n (mean ± SD) 0.5 ± 0.6
 range 0–2
Glaucoma diagnosis, n
 POWG 33
 PEX 14
 PDG 4
 nTG 5
 OhT 2
 PACG 2
Applied intraoperative MMC, n
 0.01% 2
 0.02% 52
 0.05% 7
Second operations, n (mean ± SD) 1 ± 1
 range 0–4
Laser suture lysis, n (mean ± SD) 1 ± 1.4
 range 0–7
Abbreviations: MMC, mitomycin C; n, number; nTG, normal tension glaucoma; 
OD, right eye; OhT, ocular hypertension; OS, left eye; PACG, primary angle closure 
glaucoma; PDG, pigment dispersion glaucoma; PEX, pseudoexfoliation glaucoma; 
POWG, primary open angle glaucoma; SD, standard deviation.
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Table 2 Preoperative and postoperative comparisons
5-FU group 5-FU and bevacizumab  
group
Total P-value between 
groups
Antiglaucomatous medications, n (mean ± SD)
 Preoperative 2.1 ± 1.0 2.5 ± 0.9 2.3 ± 1 0.121
 range 0–4 1–4 0–4
 Postoperative 0.1 ± 0.4 0.2 ± 0.5 0.2 ± 0.5 0.434
 range 0–2 0–2 0–2
Preoperative lens status, n
 Phakic 31 21 52 0.167
 Pseudophakic 3 6 9
Lens status 12 months/last follow-up, n
 Phakic 26 16 42 0.174
 Pseudophakic 8 11 19
IOP, mmhg (mean ± SD, range)
 Preoperative 24 ± 6 (15–37) 24 ± 6 (14–37) 24 ± 6 (14–37) 0.989
 Postoperative 12 ± 2 (8 –17) 11 ± 3 (6–16) 12 ± 3 (6–17) 0.380
BCVA, decimal
 Preoperative 0.8 0.62 0.213
 Postoperative 0.8 0.35 0.162
Visual field (MD ± SD, range)
 Preoperative 7.5 ± 7 (-1.1 to 22.1) 10.5 ± 7.6 (0–23.9) 9 ± 7.3 (-1.1 to 23.9) 0.126
 Postoperative 8.2 ± 6.3 (1.3–21.7) 12.0 ± 7.7 (0.9–24.0) 10 ± 7.1 (0.9–24) 0.106
Complete successa 78.79% (n = 26) 85.19% (n = 23) 81.67% (n = 49) 0.739
Complete successb 84.85% (n = 28) 81.48% (n = 22) 83.33% (n = 50) 0.742
Qualified successc 85.29% (n = 29) 100.0% (n = 27) 91.80% (n = 56) 0.060
Qualified successd 100.0% (n = 34) 100.0% (n = 27) 100.0% (n = 61) 1
Notes: aIOP # 21 mmhg and .20% pressure reduction from baseline; bIOP # 18 mmhg without glaucoma medication at the last follow–up; can IOP # 21 mmhg 
and .20% pressure reduction from baseline; and dIOP # 18 mmhg with and without glaucoma medication at the last follow-up. “Postoperative” indicates the time point at 
last follow-up. The comparison here is between preoperative and last follow up (postoperative time point: last follow up).
Abbreviations: 5-FU, 5-fluororacil; BCVA, best corrected visual acuity; IOP, intraocular pressure; MD, mean deviance; SD, standard deviation.
Discussion
VEGF has been described to have multiple effects on wound 
healing, such as angiogenesis and enhancement of scar 
formation.7,8 It has also been shown to be elevated in glaucoma 
patients.9–11 Therefore, bevacizumab, as a VEGF antibody, 
may have the potential to reduce elevated VEGF levels, 
angiogenesis, and scar formation.12 Current case reports and 
studies in animals have shown a tendency for reduced bleb 
failure and postoperative scarring after subconjunctival injec-
tions of bevacizumab as an adjunct to 5-FU or when used 
alone.13–17 Memarzadeh et al reported a significant reduction 
in postoperative scarring on a microscopic level and prolonged 
bleb survival when comparing bevacizumab to 5-FU and a 
balanced salt solution, respectively, in rabbits, even though 
a statistically significant difference in IOP reduction could 
not be found.17 Esson et al reported an increase in VEGF 
in the bleb tissue of rats and Li et al reported an increase in 
VEGF in the aqueous humor of rabbits.20,21 The application of 
bevacizumab subconjunctivally and into the anterior chamber 
intraoperatively did not lead to a better IOP lowering, but to a 
larger bleb area after the Moorfields bleb classification, thus 
implementing a reduction in scar formation.21 These animal 
studies may implicate a possible benefit in applying postopera-
tive bevacizumab to suppress further upregulation of VEGF 
production. How et al reported the highest bleb survival rate 
in a rabbit model when subconjunctival bevacizumab was 
combined with 5-FU (100%).16 Interestingly, the applica-
tion of bevacizumab alone still led to a higher survival rate 
(50%) than 5-FU (25%) alone.16 The control group showed no 
bleb survival. These findings support the idea of a potential 
benefit of postoperative scar inhibition by bevacizumab, and 
are consistent with the results of this study, by reducing the 
postoperative amount of 5-FU when bevacizumab is applied 
in addition to 5-FU. The findings of the animal studies are 
also consistent with published in vitro studies. O’Neill et al 
detected a reduction in fibroblast proliferation and collagen 
gel contraction ability after bevacizumab application.23 
Li et al reported a significant increase in human and rabbit 
tenon fibroblast proliferation in tissue culture when VEGF 
was added.21 To date, only a few case reports and pilot stud-
ies on glaucoma patients have looked at the effect of VEGF 
inhibitors to  prevent  postoperative scarring.13,14 In a pilot 
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Figure 1 Intraocular pressure values preoperative to 12 months/last follow-up.
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study, Grewal et al injected bevacizumab subconjunctivally 
at the end of  trabeculectomy.14 Twelve eyes were observed 
and after a mean follow-up period of 182 days, a successful 
trabeculectomy with respect to IOP control was observed in 
11 eyes (92%), with an average IOP reduction of 52%.14 An 
open label pilot study by Kahook et al injected ranibizumab 
in addition to MMC and compared this with MMC alone.13 
Statistically significant differences in peripheral bleb area, 
peripheral bleb vascularity, nonbleb-related peripheral con-
junctiva vascularity, and more diffuse blebs with a lower 
degree of vascularity were found in the group with intravitreal 
ranibizumab.
Postoperative scarring remains the most frequent cause 
for bleb failure and thus a rise in IOP after filtering surgery3 
makes it necessary to inhibit scar formation.  Antimetabolites, 
such as 5-FU and MMC, are the current standard to prevent 
blebs from postoperative scar formation.4 The described com-
plications of antimetabolites, such as bleb leakage, hypotony, 
corneal scarring, and endophthalmitis5,6 support the potential 
benefit of bevacizumab. In this study, less postoperative 
complications, such as hypotony and re-interventions, were 
found in group 2, even though these differences were not 
statistically significant. In both groups of this study, the com-
plication rate increased with the number of 5-FU injections 
applied. Bevacizumab decreases the need for 5-FU and thus 
reduces the postoperative complication rate. The increased 
levels of VEGF in glaucoma patients and TET operated 
eyes, as well as the inhibition of scar formation and the 
positive effect on bleb function, further support the potential 
benefit of bevacizumab as a postoperative inhibitor of scar 
formation.13,14,16,17,21,22 Even though a statistically significant 
difference in IOP and bleb morphology could not be found in 
this study, the additional injection of bevacizumab reduced 
the number of 5-FU injections.
It is uncertain whether topical, subconjunctival, or intra-
vitreal administration is the optimal route for administration 
of bevacizumab. Most studies focus on bevacizumab applica-
tion for retinal use. A study by Nomoto et al in rabbit eyes 
has shown that bevacizumab applied subconjunctivally had 
a longer half-life than intravitreal application.24 This may 
indicate that subconjunctival injection is the optimal route for 
administration. Further studies are needed to determine the 
optimal route for application of bevacizumab for the inhibi-
tion of scarring on the bleb area, as well as the optimal time of 
application and dosage. The dosage of bevacizumab in animal 
studies ranged from 1.25 mg bevacizumab applied 1–7 times 
subconjunctivally, to 2.5 mg applied subconjunctivally, and 
1.25 mg applied intravitreal.12,16,17 In patients, 1.5 mg of bevaci-
zumab and 0.5 mg of ranibizumab were injected in comparison 
to 3.5 mg of bevacizumab in our study.13,14 These differences 
in dosage, time of application, and route of application make 
comparisons of these studies difficult. Nevertheless, in vitro 
studies, animal studies, and studies in glaucoma patients all 
support the potential benefit of bevacizumab as an inhibitor 
of postoperative scar formation after TET.
This study has shown a reduction in the number of 5-FU 
applications when bevacizumab was applied as an adjunct, and 
is followed by similar success rates. More postoperative com-
plications occurred in patients with a higher number of 5-FU 
applications. Now, further prospective, randomized studies 
are needed to investigate the effect of subconjunctival bevaci-
zumab alone or as an adjunct to 5-FU versus 5-FU respectively 
in postoperative care after TET and to determine an optimal 
route of application, time of application, and dosage.
Table 3 Postoperative complications and interventions
5-FU group 5-FU and bevacizumab  
group
Total P-value between 
the groups
Bleb failure
 Bleb needling 14 4 20 0.046
 re-TET 3 0 3 0.248
 YAG-goniopuncture 0 2 2 0.192
 Cyclophotocoagulation 1 0 1 1
hypotony
 Resutures of the scleral flap 7 1 8 0.066
  Injection of healon-GV®  
(Abbott Laboratories Inc,  
Abbot Park, IL, USA)
1 0 1 1
Others
 Irrigation of the AC 1 0 1 1
 Iris repositioning 2 2 4 1
Abbreviations: AC, anterior chamber; Re-TET, re-trabeculectomy; YAG, yttrium aluminum garnet; 5-FU, 5-fluororacil.
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